• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Geographic location of buprenorphine-waivered physicians and integration with health systems.获得丁丙诺啡豁免权的医生的地理位置以及与医疗系统的整合。
J Subst Abuse Treat. 2020 Aug;115:108034. doi: 10.1016/j.jsat.2020.108034. Epub 2020 May 12.
2
Prescribing patterns of buprenorphine waivered physicians.有资格开丁丙诺啡的医师的处方模式。
Drug Alcohol Depend. 2017 Dec 1;181:213-218. doi: 10.1016/j.drugalcdep.2017.10.002. Epub 2017 Oct 18.
3
A bridge too far? Distance to waivered physicians and utilization of buprenorphine treatment for opioid use disorder in West Virginia Medicaid.是否为时过晚?西弗吉尼亚州医疗补助计划中,距离动摇的医生和使用丁丙诺啡治疗阿片类药物使用障碍的距离。
Subst Abus. 2022;43(1):682-690. doi: 10.1080/08897077.2021.1986882.
4
Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waivered prescriber supply.执业护士和医师助理中丁丙诺啡豁免处方的采用情况:现有豁免处方开具者供应的作用。
J Subst Abuse Treat. 2020 Aug;115:108032. doi: 10.1016/j.jsat.2020.108032. Epub 2020 May 13.
5
Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.持 DEA 豁免权开具丁丙诺啡用于治疗阿片类药物使用障碍的提供者的地理分布:5 年更新。
J Rural Health. 2019 Jan;35(1):108-112. doi: 10.1111/jrh.12307. Epub 2018 Jun 20.
6
Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements.放松 X 豁免培训要求后丁丙诺啡的处方特征。
JAMA Netw Open. 2024 Aug 1;7(8):e2425999. doi: 10.1001/jamanetworkopen.2024.25999.
7
Physicians' satisfaction with providing buprenorphine treatment.医生对提供丁丙诺啡治疗的满意度。
Addict Sci Clin Pract. 2019 Aug 26;14(1):34. doi: 10.1186/s13722-019-0163-3.
8
U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018.2016 年和 2018 年美国具有开具丁丙诺啡用于治疗阿片类药物使用障碍处方豁免资质的提供者供应趋势。
Drug Alcohol Depend. 2019 Nov 1;204:107527. doi: 10.1016/j.drugalcdep.2019.06.029. Epub 2019 Aug 30.
9
Prevalence, Distribution, and Characteristics Associated With Possession of Buprenorphine Waivers Among Infectious Diseases Physicians in the United States.美国传染病医生中拥有丁丙诺啡豁免权的患病率、分布情况及相关特征
Clin Infect Dis. 2023 Apr 3;76(7):1197-1204. doi: 10.1093/cid/ciac909.
10
Geographic and specialty distribution of US physicians trained to treat opioid use disorder.接受过治疗阿片类药物使用障碍培训的美国医生的地理分布和专业分布。
Ann Fam Med. 2015 Jan-Feb;13(1):23-6. doi: 10.1370/afm.1735.

引用本文的文献

1
"Just Google It": A Qualitative Study of Reproductive-Age Women's Stigmatizing Experiences When Accessing Buprenorphine for Opioid Use Disorder.“去谷歌搜一下就行”:一项关于育龄女性在获取丁丙诺啡治疗阿片类物质使用障碍时所遭受污名化经历的定性研究
Womens Health Issues. 2025 Jan-Feb;35(1):45-53. doi: 10.1016/j.whi.2024.10.003. Epub 2024 Nov 26.
2
At a Crossroads: Opioid Use Disorder, the X-Waiver, and the Road Ahead.处于十字路口:阿片类物质使用障碍、X豁免权及未来之路
Ochsner J. 2024 Summer;24(2):108-117. doi: 10.31486/toj.23.0074.
3
Differences in buprenorphine prescribing readiness among primary care professionals with and without X-waiver training in the US.美国有和没有 X 豁免培训的初级保健专业人员在丁丙诺啡处方准备方面的差异。
Harm Reduct J. 2023 Dec 21;20(1):180. doi: 10.1186/s12954-023-00918-3.
4
Impact of Policy Change on Access to Medication for Opioid Use Disorder in Primary Care.政策变化对基层医疗中阿片类药物使用障碍药物获取的影响。
South Med J. 2023 Apr;116(4):333-340. doi: 10.14423/SMJ.0000000000001544.
5
Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.多物质使用障碍与医疗补助受益的阿片类药物使用障碍患者的治疗质量之间的关联。
J Subst Abuse Treat. 2023 Jan;144:108921. doi: 10.1016/j.jsat.2022.108921. Epub 2022 Oct 27.
6
Medicaid Managed Care: Access To Primary Care Providers Who Prescribe Buprenorphine.医疗补助管理式医疗:获得开具丁丙诺啡的初级保健提供者的途径。
Health Aff (Millwood). 2022 Jun;41(6):901-910. doi: 10.1377/hlthaff.2021.01719.
7
Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.2019 年美国需要阿片类药物治疗的青少年和成年人中,阿片类药物使用障碍药物治疗的使用情况。
JAMA Netw Open. 2022 Mar 1;5(3):e223821. doi: 10.1001/jamanetworkopen.2022.3821.
8
Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study.基于医院的策略解决美国阿片类药物泛滥的临床影响、成本和成本效益:一项建模研究。
Lancet Public Health. 2022 Jan;7(1):e56-e64. doi: 10.1016/S2468-2667(21)00248-6. Epub 2021 Nov 30.
9
A Resident-Led Intervention to Increase Initiation of Buprenorphine Maintenance for Hospitalized Patients With Opioid Use Disorder.以住院患者为中心的干预措施增加阿片类药物使用障碍患者丁丙诺啡维持治疗的启动率。
J Hosp Med. 2021 Jun;16(6):339-344. doi: 10.12788/jhm.3544.
10
It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver.它将分阶段结束:一项在 X 豁免后将“涉猎者”纳入丁丙诺啡劳动力的策略。
Subst Abus. 2021;42(2):153-157. doi: 10.1080/08897077.2021.1903659. Epub 2021 Apr 2.

本文引用的文献

1
Buprenorphine Treatment Divide by Race/Ethnicity and Payment.美沙酮治疗按种族/民族和支付方式划分。
JAMA Psychiatry. 2019 Sep 1;76(9):979-981. doi: 10.1001/jamapsychiatry.2019.0876.
2
Medication-Based Treatment to Address Opioid Use Disorder.基于药物的阿片类物质使用障碍治疗方法。
JAMA. 2019 Jun 4;321(21):2071-2072. doi: 10.1001/jama.2019.5523.
3
"Maybe if I stop the drugs, then maybe they'd care?"-hospital care experiences of people who use drugs.“也许如果我停止吸毒,他们可能会在乎?”——吸毒者的医院护理体验。
Harm Reduct J. 2019 Feb 13;16(1):16. doi: 10.1186/s12954-019-0285-7.
4
Changes in Outpatient Services and Medication Use Following a Non-fatal Opioid Overdose in the West Virginia Medicaid Program.西弗吉尼亚医疗补助计划中阿片类药物非致命过量服用后门诊服务及用药情况的变化
J Gen Intern Med. 2019 Jun;34(6):789-791. doi: 10.1007/s11606-018-4817-8.
5
Trends In Buprenorphine Prescribing By Physician Specialty.医生专业的丁丙诺啡处方趋势。
Health Aff (Millwood). 2019 Jan;38(1):24-28. doi: 10.1377/hlthaff.2018.05145.
6
Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.持 DEA 豁免权开具丁丙诺啡用于治疗阿片类药物使用障碍的提供者的地理分布:5 年更新。
J Rural Health. 2019 Jan;35(1):108-112. doi: 10.1111/jrh.12307. Epub 2018 Jun 20.
7
Leveraging Diverse Data Sources to Identify and Describe U.S. Health Care Delivery Systems.利用多样化数据源识别和描述美国医疗保健提供系统。
EGEMS (Wash DC). 2017 Dec 15;5(3):9. doi: 10.5334/egems.200.
8
Rural And Nonrural Primary Care Physician Practices Increasingly Rely On Nurse Practitioners.农村和非农村初级保健医生的实践越来越依赖于执业护士。
Health Aff (Millwood). 2018 Jun;37(6):908-914. doi: 10.1377/hlthaff.2017.1158.
9
Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.解决美沙酮类物质处方障碍的政策途径。
Am J Prev Med. 2018 Jun;54(6 Suppl 3):S230-S242. doi: 10.1016/j.amepre.2017.12.022.
10
Market environment and Medicaid acceptance: What influences the access gap?市场环境与医疗补助接受情况:是什么影响了获取差距?
Health Econ. 2017 Dec;26(12):1759-1766. doi: 10.1002/hec.3497. Epub 2017 Mar 28.

获得丁丙诺啡豁免权的医生的地理位置以及与医疗系统的整合。

Geographic location of buprenorphine-waivered physicians and integration with health systems.

作者信息

Saloner Brendan, Lin LeeKai, Simon Kosali

机构信息

Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Room 344, Baltimore, MD 21205, United States of America.

Tunghai University, Department of Economics, No. 1727, Section 4, Taiwan Boulevard, Xitun District, Taichung City, Taiwan.

出版信息

J Subst Abuse Treat. 2020 Aug;115:108034. doi: 10.1016/j.jsat.2020.108034. Epub 2020 May 12.

DOI:10.1016/j.jsat.2020.108034
PMID:32600622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7327133/
Abstract

Efforts are underway to expand buprenorphine treatment for opioid use disorder (OUD) in hospitals and affiliated health systems, yet we do not know whether physicians who prescribe buprenorphine are likely to be health-system affiliated. Our study draws upon SK&A data covering primary care physicians and psychiatrists in eight states (California, Florida, Georgia, Maryland, Ohio, Rhode Island, Wisconsin, and West Virginia), which were linked to a list of waivered buprenorphine prescribers from the U.S. Drug Enforcement Agency. We calculated waivered rates stratified by patient limits, physician type, health system affiliation, and area-level characteristics. We mapped the spatial relationship between hospitals and waivered physicians in four metro areas. We found that primary care physicians affiliated with hospital health systems were less likely to have waivers than unaffiliated physicians (3.6% versus 8.2%), but the reverse was true for psychiatrists (33.2% versus 26.2%). Waivered physicians affiliated with health systems were less likely to practice in high-poverty areas than unaffiliated counterparts, and affiliated physicians were also more likely to cluster near hospitals. Health systems may be able to improve access to buprenorphine treatment in their communities by creating either incentives or mandates for more affiliated physicians to obtain a waiver.

摘要

目前正在努力扩大医院及附属卫生系统中丁丙诺啡用于治疗阿片类物质使用障碍(OUD)的范围,但我们尚不清楚开具丁丙诺啡处方的医生是否可能隶属于卫生系统。我们的研究利用了SK&A数据,该数据涵盖八个州(加利福尼亚州、佛罗里达州、佐治亚州、马里兰州、俄亥俄州、罗德岛州、威斯康星州和西弗吉尼亚州)的初级保健医生和精神科医生,并与美国药物执法管理局的丁丙诺啡处方豁免医生名单相关联。我们计算了按患者限制、医生类型、卫生系统隶属关系和地区层面特征分层的豁免率。我们绘制了四个大都市地区医院与豁免医生之间的空间关系图。我们发现,隶属于医院卫生系统的初级保健医生获得豁免的可能性低于非隶属医生(3.6%对8.2%),但精神科医生的情况则相反(33.2%对26.2%)。隶属于卫生系统的豁免医生在高贫困地区执业的可能性低于非隶属同行,而且隶属医生也更有可能聚集在医院附近。卫生系统或许能够通过为更多隶属医生获得豁免创造激励措施或强制规定,来改善其所在社区获得丁丙诺啡治疗的机会。